Global Markets For Uterine Cancer Treatments And Diagnostics To Reach $21.6 Billion By 2018

According to the American Cancer Society, more than 47,000 new cases of uterine, or endometrial, cancer were diagnosed and 8,010 women died from the disease in 2012 alone. While there are currently no approved drugs for endometrial cancer, researchers are examining new drugs, combinations of drugs, and targeted therapies at various stages of pipeline development. Growth in this market is primarily driven by an increase in the prevalence rates of the disease due to the aging population, diabetes, and obesity.

BCC Research provides an in-depth analysis of the globalmarkets for uterine cancer treatments and diagnostics through its report Therapies and Diagnostics for Uterine Cancer . According to the report, this market was estimated at $17.4 billion in 2012 and is expected to reach $17.8 billion in 2013. BCC Research projects the market to grow to $21.6 billion by 2018, and register a five-year compound annual growth rate (CAGR) of 3.9% from 2013 to 2018.

 RSS Feeds – Healthcare

Use this report to:

• Gain an overview of the global market for diagnostics and therapies for uterine cancer.
• Analyze global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Examine a breakdown of the markets by diagnostics and screening, surgery, radiation therapy, and drug therapy.
• Discuss uterine cancer biology.
• Evaluate drugs approved and in the pipeline to treat the disease, including chemotherapeutic and immunotherapeutic.
• Understand the patent landscape.
• Review comprehensive profiles of key companies.

This report from BCC Research contributes to the areas of market growth in uterine cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of uterine cancer products and services. This study will be largely of interest to the pharmaceutical and biotechnology industries, as well as clinics, hospitals, and research institutes. This report will also prove crucial for investment firms in the relative sector.